Simplified scoring system for predicting mortality after percutaneous coronary intervention  by Qureshi, Mansoor A et al.
Interventional Cardiology
Simplified Scoring System for Predicting
Mortality After Percutaneous Coronary Intervention
Mansoor A. Qureshi, MD, Robert D. Safian, MD, Cindy L. Grines, MD, James A. Goldstein, MD,
Douglas C. Westveer, MD, Susan Glazier, RN, BSN, Mamtha Balasubramanian, BS,
William W. O’Neill, MD
Royal Oak, Michigan
OBJECTIVES We sought to develop a simplified scoring system based on pre-intervention clinical
characteristics to predict in-hospital mortality after percutaneous coronary intervention
(PCI).
BACKGROUND Percutaneous coronary intervention is associated with variety of complications, including the
risk of death. Factors leading to poor outcomes need to be identified. Currently available
indexes are cumbersome and therefore seldom used.
METHODS Crude mortality and univariate odds ratios (ORs) for mortality associated with multiple
clinical characteristics were calculated for 9,954 patients undergoing PCI at the William
Beaumont Hospital during 1996 to 1998. Based on the OR, each factor was assigned a
weighted score. Using these scores, a classification was constructed to determine the
probability of death after PCI, with classes I through IV representing an increasing
probability of procedural mortality. This classification was validated in a separate group of
patients.
RESULTS The factors with the highest univariate odds of dying and their scores were: myocardial
infarction 14 days  7; elevated creatinine  4; multivessel disease  4; and age
65 years  3. Classes were created based on the presence of these factors in a given patient.
The odds of dying and mortality increased significantly with each class. These results were
reproduced in the validation subset.
CONCLUSIONS Preprocedural clinical risk factors have a differential influence on the probability of death after
PCI. Risk classification based on these factors can be used to accurately predict the procedural
outcome. This simple classification can be used by interventionalists to assist in management
decisions, to provide an estimate of procedural risk to the patients and relatives, and for
quality assurance. (J Am Coll Cardiol 2003;42:1890–5) © 2003 by the American College
of Cardiology Foundation
Since the introduction of balloon angioplasty in the late
1970s (1), there have been dramatic advances in the success
and safety (2–5) of percutaneous coronary intervention
(PCI). This has been coupled with an exponential increase
in the number of patients undergoing percutaneous treat-
ment for stable angina, as well as acute coronary syndromes
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(6–14). As technical refinements, including stent use (15)
and glycoprotein receptor antagonist use (16,17), have
become widespread, anatomic lesion characteristics have
become less predictive of a poor outcome. At present,
clinical characteristics such as patient age, renal function,
and the presence of acute coronary syndrome have taken a
predominant role in determining the procedural risk of
death (18–20).
Estimation of operative mortality is important for pa-
tients seeking health care, physicians making management
decisions, and institutions for quality assurance purposes.
Investigators have utilized clinical and angiographic char-
acteristics to assess the risk of major adverse events in
various patient cohorts undergoing PCI (18,21–25). Most
of these methods either evaluate multiple clinical and
angiographic features or use complex mathematical equa-
tions, and thus are difficult to use to risk stratify patients.
The goal of this study was to derive a simple scoring
system based solely on preprocedural clinical features, which
would provide risk classes predictive of mortality after PCI.
Furthermore, we attempted to validate this scoring system
on a different patient population. Most of the predictors of
major complications identified in this study have been
described previously (2,19,26–37).
METHODS
Patient population. All patients undergoing PCI at the
William Beaumont Hospital between January 1996 to
December 1998 were studied (n  9,954). Demographic,
clinical, and procedural data were recorded for all patients in
a dedicated database. The in-hospital outcome was carefully
monitored and recorded by quality assurance nursing per-
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sonnel trained and dedicated to catheterization laboratory
and chart review. Data were prospectively collected on age,
gender, coronary risk factors, renal function (serum creati-
nine), the presence of coronary artery disease (50% diam-
eter stenosis by angiography), a recent myocardial infarction
(MI) (PCI within 14 days of MI), a history of coronary
artery bypass graft surgery (CABG), and a history of
peripheral vascular disease (PVD). (For the diagnosis of MI,
two of the following criteria had to be present: chest pain
30 min, creatine kinase elevation2 times the upper limit
of normal, and electrocardiographic changes consistent with
MI. If there was a history of lower extremity vascular disease
or carotid artery disease, PVD was considered present.)
Procedures were performed by interventional cardiologists
who are required to be American Board of Internal Medi-
cine cardiology board certified and who must meet minimal
proficiency criteria of performance of 75 interventional
cases per year. Percutaneous transluminal coronary angio-
plasty and stent placement were the predominant modes of
revascularization. Procedural activated clotting times were
maintained at 300 to 350 s, unless glycoprotein IIb/IIIa
agents were used. Patients undergoing PCI from 1999 to
November 2001 (n  12,005) at the William Beaumont
Hospital were used as a validation subset.
End point. In-hospital mortality was the primary end
point of the study. This included all-cause mortality in the
catheterization laboratory and during the hospital stay after
the procedure.
Statistical analysis. Crude mortality and the univariate
odd ratio (OR) of mortality for various clinical factors were
calculated. Individual risk factors that were significant on
the univariate analysis were entered into a stepwise, multiple
logistic regression model to determine the most parsimoni-
ous model that best predicted mortality. To simplify the
analysis, four clinical factors that were most prevalent and
had the highest impact on mortality were used for analysis:
a history of a recent MI (patients undergoing PCI within 14
days of MI), multivessel coronary artery disease (50%
stenosis in more than one coronary artery), elevated creati-
nine (1.5 mg/dl), and age65 years. Each of these factors
was assigned a “weighted” score based on the odds of dying.
The univariate OR rounded to the nearest integer consti-
tuted the score for each factor. Risk classes (1 to 4) were
created based on the total scores obtained by the various
combinations of risk factors. Crude mortality and OR were
calculated for various classes for the entire data set and
individual years. The odds of dying for individual classes
were compared with class I. Classification system discrim-
ination was assessed by use of the area under the receiver
operating characteristic (ROC) curve (38). The area under
the ROC curves was calculated separately for all statistically
significant factors, four select factors that were considered
for the classification, and the individual classes. These were
also tested for goodness of fit by use of the Hosmer-
Lemeshow statistic (39).
This classification system was applied on the validation
subset to calculate mortality and ORs for individual classes.
The areas under the ROC curves were also calculated in the
validation set.
RESULTS
Patient population. Baseline clinical characteristics are
shown in Table 1. During the study period, data were
collected on 9,954 patients. None of the patients were
excluded from the analysis. Overall mortality was 1.4%.
Females constituted about one-third of the patients (32%);
59% of the patients had multivessel disease (MVD); 22%
had a recent MI (22%); previous CABG had been per-
Table 2. Crude Mortality, Relative Risk, Univariate Odds
Ratios, and Risk Scores for Clinical Risk Factors
Clinical Risk
Factors
Deaths/Total
(n)
Mortality
(%)
Odds
Ratio
Weighted
Scores
for Select
Factors
No risk factors 3/1,726 0.2 0.1 0
MI 14 days 92/2,118 4.3 7.4 7
Elevated creatinine 42/877 4.8 4.4 4
MVD 116/5,756 2.0 4.1 4
Age 65 yrs 100/4,668 2.1 3.0 3
Male gender 65/6,683 1.0 1.0
Female gender 71/3,136 2.2 2.3
Diabetes 59/2,717 2.2 2.0
PVD 34/1,504 2.2 1.8
Past CVA 20/925 2.1 1.6
Recent smoking 24/2,214 1.1 0.7
MI  myocardial infarction; MVD  multivessel disease; other abbreviations as in
Table 1.
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CS  cardiogenic shock
MI  myocardial infarction
MVD  multivessel disease
OR  odds ratio
PCI  percutaneous coronary intervention
PVD  peripheral vascular disease
ROC  receiver operating characteristic
Table 1. Baseline Clinical Characteristics in the Derivation and
Validation Subsets
Clinical Risk
Factors
Derivation Set
(n  9,954)
Validation Set
(n  12,005) p Value
Multivessel disease 59.0 60.9 0.0005
Age 65 yrs 47.9 50.7  0.0001
Females 32.2 31.4 0.2
Diabetes 27.9 29.1 0.047
Recent smoking 22.5 18.9  0.0001
Previous CABG 21.4 24.1  0.0001
PVD 15.5 16.3 0.08
Past CVA 9.5 8.6 0.014
Elevated creatinine 9.2 11.7  0.0001
Data are expressed as percentages.
CABG  coronary artery bypass graft surgery; CVA  cerebrovascular accident;
PVD  peripheral vascular disease.
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formed in 21.4%; and about 9% of patients had creatinine
1.5 mg/dl at the time of the procedure. It can be noticed
that the derivation subset was more likely to have had
patients with previous CABG, a past cerebrovascular acci-
dent, and recent smokers. On the other hand, patients in the
validation subset were more likely to be older, with MVD,
to have elevated creatinine, and to have been recent
smokers.
Influence of various risk factors and the classification
system in the derivation subset. Overall mortality for
patients undergoing PCI from 1996 to 1998 (n  9,954)
was 1.4%. The univariate ORs for mortality for some of the
clinical factors studied are shown in Table 2. It can be
noticed that the highest individual univariate ORs are for
MI 14 days (7.4), elevated creatinine (4.4), MVD (4.1),
age 65 years (3.0). (Patients with cardiogenic shock [CS]
were not analyzed separately and were included in the
patients with MI 14 days. However, the univariate OR of
patients who presented with MI14 days and CS was 52.6,
which is higher than any of the other factors studied
separately. On the other hand, for those with MI 14 days
without CS, the OR was 5.3.) As described earlier, these
factors were given individual scores based on univariate OR:
MI 14 days  7; elevated creatinine  4; MVD  4; and
age 65 years  3. The classes with their ORs and
mortality and scores are shown in Table 3. Multiple logistic
regression analysis was also performed on these clinical
factors (Table 4). The area under the ROC curve was
computed for statistically significant factors. The average
area under the ROC curve for the multiple logistic regres-
sion analysis for all significant factors studied was 0.87. It
dropped only to 0.84 when the top four risk factors were
considered, showing that these select factors still predict the
overall outcome. The Hosmer-Lemeshow statistic was not
significant for either of these analyses, showing little depar-
ture from a perfect fit (Table 5).
According to this classification, patients with no risk
factors were in class I. Possible risk factor combinations that
will put patients in different classes are shown in Table 6.
The area under the ROC curve for this classification is 0.81,
with an insignificant Hosmer-Lemeshow p value, implying
that this model fit has little departure from a perfect fit
(Table 5). There appears to be a definite gradation in
mortality as the classes increase. An increase in the score
seems to be associated with a striking increase in the odds of
dying and a significant increase in the crude mortality.
Thus, the classification appears to distinguish patients who
are at an increased risk of dying after PCI.
Figure 1 shows the distribution of patients in various
classes. The majority of the patients fall in class II; class IV
has the fewest number of patients.
Validation. We applied this scoring system for all patients
undergoing PCI from January 1999 to November 2001 (n
12,005). Figure 2 compares the crude mortality for individ-
ual classes between the derivation and validation subset. It is
apparent that classes show similar gradation in mortality
and OR, as seen in patients undergoing PCI over the period
1996 to 1998, who constituted the basis of our classification.
The area under the ROC curve was 0.87 for the logistic
regression model, which included all of the statistically
significant factors, and 0.83 for the classification, consistent
with excellent discrimination (Table 5).
DISCUSSION
This report presents the largest single-center database of
patients undergoing PCI, which includes prospectively col-
lected data on various important clinical variables that could
influence the procedural outcome. It represents a wide
variety of patients presenting to the catheterization labora-
tory with diverse clinical presentations, ranging from stable
angina to CS. Because all patients were analyzed, this
database provides outcome evaluation of a very contempo-
rary interventional patient population.
Mortality data. The yearly mortality of the patient popu-
lation in the derivation ranges between 1.1% and 1.7%
(mean 1.36%). This rate resembles those found in diverse
Table 3. Risk Classification
Risk
Classes Score Mortality OR (CI)* p Value*
I 0 0.2 1.0
II 3–8 0.5 4.4 (1–19) 0.02
III 9–11 2.3 19.5 (5–81)  0.0001
IV 12–18 9.1 76.8 (19–313)  0.0001
*These values are compared with class I.
CI  confidence interval; OR  odds ratio.
Table 4. Multivariate Logistic Regression Model of In-Hospital Mortality
Significant
Variables
Parameter
Estimates
Odds
Ratio 95% CI p Value
Intercept 7.1912  0.0001
Elevated creatinine 0.7211 2.057 1.320–3.206  0.0001
Age 65 yrs 0.6694 0.512 0.353–0.744  0.0001
MI 14 days 0.7621 2.143 1.174–3.911  0.0001
MVD 0.7866 2.196 1.455–3.313  0.0001
Gender 1.2734 3.573 2.350–5.4320  0.0001
Elevated cholesterol 1.1891 3.284 1.984–5.437 0.0002
PVD 1.1675 3.214 1.880–5.493 0.0005
Diabetes 0.4338 1.543 1.065–2.235 0.0210
CI  confidence interval; other abbreviations as in Tables 1 and 2.
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patient cohorts reported by various investigators. Procedural
mortality in contemporary PCI has generally remained
low, despite the increasing complexity of procedures
(2,19,30,40–44). Because a widely accepted risk-adjusted
mortality rate does not exist, analysis of subgroups like those
we report may provide meaningful information on operator
and institutional outcomes.
Risk factors. To establish risk factors that adversely in-
fluence mortality, we evaluated predictors that have
been previously identified in various registry databases
(2,19,21,26–36,45,46). Our goal was to use preprocedural
clinical factors and not include procedural factors for the
prediction of mortality. Recent MI and elevated creatinine
were found to have the highest mortality and individual
odds of dying. These findings are similar to the observations
of Moscucci et al. (20). The presence of MVD and
increasing age were the other factors with a strong influence
on mortality.
As mentioned earlier, CS was found to be the strongest
predictor of mortality, with an OR of 52.6 in the derivation
group. However, these patients were not separated from the
“MI 14 days” subgroup. This allowed us to evaluate the
overall influence of MI 14 days on postprocedural mor-
tality.
Risk classification. Investigators have attempted to derive
various predictive models for post–coronary interventional
procedure outcomes. These include complex computerized
models or indexes that consider both clinical and procedural
factors. Kimmel et al. (18) described a predictive index that
includes death, MI, and emergency CABG as procedure-
related complications. Budde et al. (23) described a com-
puter model (INTERVENT) that would predict postpro-
cedural complications. This model relies on multiple clinical
and procedural factors. Recently, Moscucci et al. (20)
presented a predictive tool for in-hospital mortality. Their
findings resemble ours to some extent, as increasing age,
elevated creatinine, recent MI, and MVD appear to be the
dominant factors influencing mortality. Similarly, this latter
group also used weighted scores for individual risk factors.
However, contrary to our analysis, a combination of demo-
graphics and procedural variables was used for risk assess-
ment, which can make pre-PCI risk assessment somewhat
difficult.
With our classification, use of only four clinical variables
can give us an accurate idea about post-PCI risk of death.
These calculations can be performed within seconds and do
not require complex mathematical calculations.
Validation. It is extremely important to validate predictive
models in different patient populations, as technical ad-
vances, adjunctive pharmacology, and indications for PCI
change rapidly. It is also important to assess the durability of
this risk score. It can be noted that this classification
provides similar results in a large validation subset (Fig. 2)
with distinct patient cohorts that significantly differ in
mortality. Despite differences in baseline characteristics
(Table 1), the classification’s ability to predict mortality does
not seem to be decreased (Fig. 2).
Risk classification was made known to the intervention-
alists at our institution in early 1999, and concern was
voiced regarding the mortality trends. This was followed by
Table 5. Area Under the Receiver Operating Characteristic Curve for All Significant Factors,
Four Selected Factors, and Risk Classes for the Derivation and Validation Subsets
Derivation Set Validation Set
All
Significant
Variables
4 Selected
Variables
Risk
Classes
All
Significant
Variables
4 Selected
Variables
Risk
Classes
Area under ROC curve 0.874 0.839 0.810 0.877 0.851 0.825
Hosmer-Lemeshow
goodness-of-fit statistic
(p value)
0.7092 0.4153 0.9913 0.3388 0.9498 0.1628
ROC  receiver operating characteristic.
Table 6. Various Combinations of Risk Factors That Would Fit
Individual Risk Classes
Risk Classes Various Possible Combinations of Risk Factors
I None of the selected 4 risk factors
II Each of the factors individually, age  creatinine,
age  MVD, creatinine  MVD
III MI  age, MI  MVD, MI  creatinine,
age  creatinine  MVD
IV MI  at least 2 other factors
Abbreviations as in Table 2.
Figure 1. Distribution of patients into various risk classes in the derivation
and validation subsets.
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a distinct downward trend in procedural mortality (Fig. 3).
This statistically significant decline in mortality could be
due to a variety of reasons. Figure 1 shows that there is a
distinct decrease in patients fitting into class IV in years
1999 to 2001 (7.0% to 5.9% in the derivation and validation
subsets, respectively). In addition, there was a decrease in
mortality for this class in the validation subset (9.1% vs.
7.1% in the derivation and validation subsets, respectively).
Thus, a decrease in mortality in the validation subset could
be related to both a decrease in PCI for high-risk cases and
an improved outcome in these patients. Additional expla-
nations may include increasing awareness of the risk result-
ing in the use of adjunctive medications (glycoprotein
IIb/IIIa inhibitors) and devices, as well as elimination of
factors that may lead to prolongation of the procedure.
These factors are being currently evaluated.
Clinical implications. We have shown that despite tech-
nical advancements, preprocedural clinical factors have a
strong influence on mortality. These factors can be used to
accurately predict postprocedural mortality at the bedside.
This can help physicians make triage decisions and provide
patients and families with accurate risk assessment.
This simplified classification can help in quality assur-
ance, because mortality trends for individual classes can be
tracked for the physicians and institutions. Finally, risk
classes can also help interventionalists identify patients who
may be candidates for adjuvant therapies, aggressive nurs-
ing, and hemodynamic monitoring.
Study limitations. This classification uses a small group of
risk factors which may underestimate the influence of other
potentially important factors. Lesion characteristics and left
ventricular function are not incorporated and may improve
the precision of this tool.
Procedural factors such as contrast load also play a
significant role in determining outcomes; however, our goal
was to determine risk based on preprocedural clinical factors
that were easy to obtain and available in all patients before
initiation of the intervention.
This classification merely assigns a risk class to a patient
and describes the probability of mortality; however, it does
not predict individual patient outcome.
Another potential limitation is the fact that the data were
derived from a single center, and one would have to be
cautious in generalizing these findings.
Conclusions. Preprocedural clinical risk factors strongly
influence hospital mortality after PCI. These factors can be
used to derive the probability of dying after PCI.
Using the presence or absence of four risk factors (i.e., MI
14 days, MVD, elevated creatinine [1.5 mg/dl], age
65 years), patients can be classified into different risk
classes, with mortality ranging from 0.2% to 9.1%. This risk
classification provides quick and accurate assessment of
postprocedural in-hospital mortality. It can be used for
quality assurance and assessment of physician and institu-
tional proficiency.
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